Moores Cancer Center
University of California UC San Diego Health
La Jolla, CA
- CAR T Cell
- BCMA
- CD19
- Phase 1/2
- Has results
Accepting patients
Elranatamab Monotherapy
Phase II MRD-Adapted Study of Elranatamab in Relapsed/Refractory
- Bispecific Antibody
- BCMA
- Phase 2
Accepting patients
OPN-662
A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma
- BET Inhibitor
- Phase 1
- Has results
Accepting patients
MajesTEC-4
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
- Bispecific Antibody
- Bispecific T Cell Engager (BiTE)
- BCMA
- Phase 3
2 hidden based on your filters.Show All